Fast diffusion of very long chain saturated fatty acids across a bilayer membrane and their rapid extraction by cyclodextrins
GLP-1R triggers various intracellular signaling pathways, such as the cAMP/PKA and PI3K/Akt pathways, by binding to endogenous GLP-1 or exogenous agonists, resulting in the enhancement of insulin secretion, inhibition of glucagon secretion, as well as anti-inflammatory and antioxidant stress response
EX long-acting preparation can reduce weight, but there are few related clinical studies, and most focus on patients with T2DM
An updated Cochrane review in 2019 of four studies with 907 participants was very uncertain as to if ALC caused a pain reduction after 6 to 12 months of treatment
If nausea remains problematic despite conservative management strategies, healthcare providers may consider maintaining a lower dose for an extended period before further escalation, or in some cases, temporarily reducing the dose